These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31642804)

  • 21. Priority setting in health care: an axiomatic bargaining approach.
    Clark D
    J Health Econ; 1995 Aug; 14(3):345-60. PubMed ID: 10145139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Payment Reform, Medication Use, and Costs: Can We Afford to Leave Out Drugs?
    Parekh N; McClellan M; Shrank WH
    J Gen Intern Med; 2019 Mar; 34(3):473-476. PubMed ID: 30604128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The economics of alternative payment models for pharmaceuticals.
    Hlávka JP; Yu JC; Goldman DP; Lakdawalla DN
    Eur J Health Econ; 2021 Jun; 22(4):559-569. PubMed ID: 33725260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value-based pricing of drugs in the UK.
    Webb DJ; Walker A
    Lancet; 2007 Apr; 369(9571):1415-1416. PubMed ID: 17467498
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost-effectiveness analysis for priority-setting in South Africa--what are the possibilities?
    Doherty J
    S Afr Med J; 2010 Dec; 100(12):816-21. PubMed ID: 21414274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Excluding NICE from early stages of value based pricing scheme was "big win for pharma," conference is told.
    Limb M
    BMJ; 2013 Nov; 347():f6906. PubMed ID: 24246840
    [No Abstract]   [Full Text] [Related]  

  • 27. Theories of justice and their implications for priority setting in health care.
    Olsen JA
    J Health Econ; 1997 Dec; 16(6):625-39. PubMed ID: 10176776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Priority-setting criteria in the Norwegian health services.
    Wisløff T
    Tidsskr Nor Laegeforen; 2015 Aug; 135(15):1373-5. PubMed ID: 26315241
    [No Abstract]   [Full Text] [Related]  

  • 29. [The reference pricing of pharmaceuticals in European countries].
    Gildeyeva GN; Starykh DA
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2013; (3):45-9. PubMed ID: 24027849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds?
    Sandmann FG; Mostardt S; Lhachimi SK; Gerber-Grote A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):475-486. PubMed ID: 29979895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. QALYs: is the value of treatment proportional to the size of the health gain?
    Nord E; Enge AU; Gundersen V
    Health Econ; 2010 May; 19(5):596-607. PubMed ID: 19459186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Priority setting in global health: towards a minimum DALY value.
    Drake T
    Health Econ; 2014 Feb; 23(2):248-52. PubMed ID: 23576492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?
    Hertzman P; Miller P; Tolley K
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):5-12. PubMed ID: 29186996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pricing schemes for new drugs: a welfare analysis.
    Levaggi R
    Soc Sci Med; 2014 Feb; 102():69-73. PubMed ID: 24565143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Should the treatment of children be the first priority?].
    Kekomäki M
    Duodecim; 1997; 113(7):551, 553. PubMed ID: 11466881
    [No Abstract]   [Full Text] [Related]  

  • 36. The Norwegian National Council for Priority Setting in Health Care: decisions and justifications.
    Wester G; Bringedal B
    Health Econ Policy Law; 2018 Apr; 13(2):118-136. PubMed ID: 28322184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage.
    Maniadakis N; Holtorf AP; Otávio Corrêa J; Gialama F; Wijaya K
    Appl Health Econ Health Policy; 2018 Oct; 16(5):591-607. PubMed ID: 29987759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.